Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Predicting Patients’ Response to Immunotherapy from Tumor Histopathology and Blood: Computational Science in Immuno-oncology

July 8, 2025 | 12:00 PM – 1:00 PM

Virtual

Add to Outlook Calendar

To register to attend, you must log in to your SITC Cancer Immunotherapy CONNECT account. Don’t have an account? Create a free one.

Join Drs. Eytan Ruppin (presenter) and Timothy Shaw (moderator) as they present on four approaches for predicting how patients respond to checkpoint immunotherapy.

  • Approach #1: Predicting patient response to the tumor bulk transcriptome
  • Approach #2: Predicting response directly from the blood via simple routine lab tests and the tumor mutational burden
  • Approach #3: Predicting patient immunotherapy response from the tumor histopathological images
  • Approach #4: Building predictors of the tumor microenvironment and developing spatially grounded biomarkers of treatment response

This webinar is part of the 2025 SITC-NCI Computational Immuno-oncology Webinar Series, which is focusing on methods and clinical utility for biomarker development in immune-oncology. This is the fifth of ten free webinars set to help individual research labs overcome the computational challenges of analyzing and integrating different assay data throughout the spectrum of immuno-oncology for biomarker development. The annual series aims to educate early-career scientists, increase participants’ awareness of and engagement in NCI-supported Immunotherapy Networks, and fulfill the goal of accelerating progress in cancer research.

Email